Indian Pharma Market’s Growth Moderates In January After A Strong December: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Indian Pharma Market growth moderated to 4.5% YoY in January 2021 versus 8.5% in December 2020 (7.6% in Jan-20), led by price/new launches of approximately 4.9%/2.4%.
This was offset to some extent by the volume decline of 2.9% YoY in January 2021.
Gastro/vitamin-mineral-nutrients/cardiac therapies exhibited a YoY growth of 14.3%/12.2%/8.8%.
Anti-Infectives therapy declined marginally (2.7% YoY) versus 5% growth in December 2020.
Respiratory sales remained in a downtrend with a 14.1% YoY decline in January 2021.
National list of essential medicines (~16% of IPM) grew 1.8% YoY, while Non-NLEM (~84%) fell 3.6% in January 2021.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.